We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
ATC
251
Adirondack Trust Company
New York
$3K +$2.58K +65 New
TPCW
252
TD Private Client Wealth
New York
$2.74K +$993 +25 +74%
PA
253
Parallel Advisors
California
$2K – – –
PWPS
254
Pinnacle Wealth Planning Services
Ohio
$2K +$1.47K +37 New
CWP
255
Concord Wealth Partners
Virginia
$2K +$1.55K +39 New
QT
256
Quantbot Technologies
New York
$2K +$1.95K +49 New
ICP
257
Interchange Capital Partners
Pennsylvania
$2K +$2.02K +51 New
Lazard Asset Management
258
Lazard Asset Management
New York
$2K +$2.42K +61 New
LSA
259
Leonteq Securities AG
Switzerland
$1.53K +$1.31K +33 New
ABC
260
Associated Banc-Corp
Wisconsin
$1K – – –
TWA
261
TCI Wealth Advisors
Arizona
$1K – – –
IA
262
Inspire Advisors
Idaho
$1K +$715 +18 New
VCG
263
Vantage Consulting Group
Virginia
$1K +$834 +21 New
Kayne Anderson Rudnick Investment Management
264
Kayne Anderson Rudnick Investment Management
California
$1K +$873 +22 New
ED
265
Exane Derivatives
France
$928 – – –
APA
266
American Portfolios Advisors
New York
$928 +$199 +5 +33%
AIG
267
American International Group
New York
$160 -$5.76K -145 -4%
APM
268
Avidity Partners Management
Texas
– -$26.3M -799,000 Closed
Point72 Asset Management
269
Point72 Asset Management
Connecticut
– -$14.6M -444,342 Closed
Balyasny Asset Management
270
Balyasny Asset Management
Illinois
– -$17.4M -437,864 Closed
PHS
271
PFM Health Sciences
California
– -$15.2M -381,990 Closed
MP
272
Mangrove Partners
Connecticut
– -$12.5M -379,188 Closed
MS
273
Maven Securities
Jersey
– -$7.88M -240,000 Closed
PM
274
Prosight Management
Texas
– -$3.97M -120,606 Closed
Alyeska Investment Group
275
Alyeska Investment Group
Illinois
– -$3.66M -111,135 Closed
9 10
11
12 13

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.